{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:07:28Z","timestamp":1768716448247,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"DOI":"10.7759\/cureus.101744","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:35:31Z","timestamp":1768667731000},"source":"Crossref","is-referenced-by-count":0,"title":["A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy"],"prefix":"10.7759","author":[{"given":"Amani S","family":"BinSharhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AlJouhrah M","family":"AlAbdullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouq F","family":"Alabdullatif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara Y","family":"Aboushark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noura  M","family":"Alateeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wala A","family":"Alhajjaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer O","family":"Alrabea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fajr","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman GK","year":"2021","unstructured":"Friedman GK, Johnston JM, Bag AK, et al.. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021, 384:1613-22. 10.1056\/NEJMoa2024947","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.11.036","article-title":"Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells","volume":"371","author":"Melen GJ","year":"2016","unstructured":"Melen GJ, Franco-Luz\u00f3n L, Ruano D, et al.. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett. 2016, 371:161-70. 10.1016\/j.canlet.2015.11.036","journal-title":"Cancer Lett"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyx507","article-title":"Phase I trial of DNX-2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patient","volume":"83","author":"Tejada S","year":"2018","unstructured":"Tejada S, Alonso M, Pati\u00f1o A, Fueyo J, Gomez-Manzano C, Diez-Valle R. Phase I trial of DNX-2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patient. Neurosurgery. 2018, 83:1050-6. 10.1093\/neuros\/nyx507","journal-title":"Neurosurgery"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(23)00031-7","article-title":"Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial","volume":"7","author":"Thompson EM","year":"2023","unstructured":"Thompson EM, Landi D, Brown MC, et al.. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. Lancet Child Adolesc Health. 2023, 7:471-8. 10.1016\/S2352-4642(23)00031-7","journal-title":"Lancet Child Adolesc Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62260-5","article-title":"The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials","volume":"16","author":"Qian X","year":"2025","unstructured":"Qian X, Ning W, Yang J, et al.. The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials. Nat Commun. 2025, 16:6934. 10.1038\/s41467-025-62260-5","journal-title":"Nat Commun"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25269","article-title":"Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed\/refractory solid tumors: a report of the Children's Oncology Group","volume":"62","author":"Burke MJ","year":"2015","unstructured":"Burke MJ, Ahern C, Weigel BJ, et al.. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed\/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer. 2015, 62:743-50. 10.1002\/pbc.25269","journal-title":"Pediatr Blood Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25464","article-title":"A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report","volume":"62","author":"Kolb EA","year":"2015","unstructured":"Kolb EA, Sampson V, Stabley D, et al.. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer. 2015, 62:751-8. 10.1002\/pbc.25464","journal-title":"Pediatr Blood Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya J","year":"2022","unstructured":"G\u00e1llego P\u00e9rez-Larraya J, Garcia-Moure M, Labiano S, et al.. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med. 2022, 386:2471-81. 10.1056\/NEJMoa2202028","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1183295","article-title":"A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors","volume":"11","author":"Moreno L","year":"2023","unstructured":"Moreno L, Teira P, Croop JM, et al.. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Front Pediatr. 2023, 11:1183295. 10.3389\/fped.2023.1183295","journal-title":"Front Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby KA","year":"2017","unstructured":"Streby KA, Geller JI, Currier MA, et al.. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017, 23:3566-74. 10.1158\/1078-0432.CCR-16-2900","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler SE","year":"2017","unstructured":"Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017, 3:841-9. 10.1001\/jamaoncol.2016.2064","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0516-0","article-title":"Oncolytic virotherapy for the treatment of malignant glioma","volume":"14","author":"Foreman PM","year":"2017","unstructured":"Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics. 2017, 14:333-44. 10.1007\/s13311-017-0516-0","journal-title":"Neurotherapeutics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: challenges and solutions","volume":"45","author":"Goradel NH","year":"2021","unstructured":"Goradel NH, Baker AT, Arashkia A, Ebrahimi N, Ghorghanlu S, Negahdari B. Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer. 2021, 45:100639. 10.1016\/j.currproblcancer.2020.100639","journal-title":"Curr Probl Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01972-2","article-title":"Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy","volume":"21","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Li Y, Chen K, Qian L, Wang P. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int. 2021, 21:262. 10.1186\/s12935-021-01972-2","journal-title":"Cancer Cell Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2023.04.001","article-title":"Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: on the way to clinical success","volume":"379","author":"Herv\u00e1s-Corpi\u00f3n I","year":"2023","unstructured":"Herv\u00e1s-Corpi\u00f3n I, Alonso MM. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: on the way to clinical success. Int Rev Cell Mol Biol. 2023, 379:169-88. 10.1016\/bs.ircmb.2023.04.001","journal-title":"Int Rev Cell Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1272351","article-title":"Recent progress in combination therapy of oncolytic vaccinia virus","volume":"15","author":"Mirbahari SN","year":"2024","unstructured":"Mirbahari SN, Da Silva M, Z\u00fa\u00f1iga AI, Kooshki Zamani N, St-Laurent G, Totonchi M, Azad T. Recent progress in combination therapy of oncolytic vaccinia virus. Front Immunol. 2024, 15:1272351. 10.3389\/fimmu.2024.1272351","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka RH","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, et al.. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015, 33:2780-8. 10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney J","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, et al.. Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018, 36:1658-67. 10.1200\/JCO.2017.73.7379","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase iii trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney JA","year":"2023","unstructured":"Chesney JA, Ribas A, Long GV, et al.. Randomized, double-blind, placebo-controlled, global phase iii trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023, 41:528-40. 10.1200\/JCO.22.00343","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang FF","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, et al.. Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018, 36:1419-27. 10.1200\/JCO.2017.75.8219","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri F","year":"2023","unstructured":"Nassiri F, Patil V, Yefet LS, et al.. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat Med. 2023, 29:1370-8. 10.1038\/s41591-023-02347-y","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano D","year":"2020","unstructured":"Ruano D, L\u00f3pez-Mart\u00edn JA, Moreno L, et al.. First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors. Mol Ther. 2020, 28:1033-42. 10.1016\/j.ymthe.2020.01.019","journal-title":"Mol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113219","article-title":"Past, present and future of oncolytic reovirus","volume":"12","author":"M\u00fcller L","year":"2020","unstructured":"M\u00fcller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers (Basel). 2020, 12:3219. 10.3390\/cancers12113219","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson A","year":"2018","unstructured":"Samson A, Scott KJ, Taggart D, et al.. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018, 10:7577. 10.1126\/scitranslmed.aam7577","journal-title":"Sci Transl Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in locoregionally advanced head and neck carcinoma","volume":"23","author":"Mell LK","year":"2017","unstructured":"Mell LK, Brumund KT, Daniels GA, et al.. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in locoregionally advanced head and neck carcinoma. Clin Cancer Res. 2017, 23:5696-702. 10.1158\/1078-0432.CCR-16-3232","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins A","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE 2nd, et al.. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018, 379:150-61. 10.1056\/NEJMoa1716435","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.09.083","article-title":"A randomized double-blind phase ii study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study","volume":"15","author":"Schenk EL","year":"2020","unstructured":"Schenk EL, Mandrekar SJ, Dy GK, et al.. A randomized double-blind phase ii study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. J Thorac Oncol. 2020, 15:110-9. 10.1016\/j.jtho.2019.09.083","journal-title":"J Thorac Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine: the world\u2019s first oncolytic virus medicine and its update in China","volume":"18","author":"Liang M","year":"2018","unstructured":"Liang M. Oncorine: the world\u2019s first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018, 18:171-6. 10.2174\/1568009618666171129221503","journal-title":"Curr Cancer Drug Targets"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7150\/jca.71992","article-title":"From immunosuppression to immunomodulation - turning cold tumours into hot","volume":"13","author":"Garofalo M","year":"2022","unstructured":"Garofalo M, Pancer KW, Wieczorek M, Staniszewska M, Salmaso S, Caliceti P, Kuryk L. From immunosuppression to immunomodulation - turning cold tumours into hot. J Cancer. 2022, 13:2884-92. 10.7150\/jca.71992","journal-title":"J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00389-3","article-title":"Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model","volume":"29","author":"Zhang H","year":"2022","unstructured":"Zhang H, Xie W, Zhang Y, et al.. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2022, 29:456-65. 10.1038\/s41417-021-00389-3","journal-title":"Cancer Gene Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207449","article-title":"Oncolytic viruses as a platform for the treatment of malignant brain tumors","volume":"21","author":"Sostoa J","year":"2020","unstructured":"Sostoa J, Dutoit V, Migliorini D. Oncolytic viruses as a platform for the treatment of malignant brain tumors. Int J Mol Sci. 2020, 21:7449. 10.3390\/ijms21207449","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/v13102103","article-title":"Effect of serial systemic and intratumoral injections of oncolytic Zika virus in mice bearing embryonal CNS tumors","volume":"13","author":"Ferreira RO","year":"2021","unstructured":"Ferreira RO, Granha I, Ferreira RS, Bueno HS, Okamoto OK, Kaid C, Zatz M. Effect of serial systemic and intratumoral injections of oncolytic Zika virus in mice bearing embryonal CNS tumors. Viruses. 2021, 13:2103. 10.3390\/v13102103","journal-title":"Viruses"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070226","article-title":"Oncolytic viruses as therapeutic tools for pediatric brain tumors","volume":"10","author":"Varela-Guruceaga M","year":"2018","unstructured":"Varela-Guruceaga M, Tejada-Sol\u00eds S, Garc\u00eda-Moure M, Fueyo J, Gomez-Manzano C, Pati\u00f1o-Garc\u00eda A, Alonso MM. Oncolytic viruses as therapeutic tools for pediatric brain tumors. Cancers (Basel). 2018, 10:226. 10.3390\/cancers10070226","journal-title":"Cancers (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100151","article-title":"Emergent and underexplored oncolytic viruses for treating pediatric central nervous system tumors","volume":"3","author":"Granha I","year":"2024","unstructured":"Granha I, Sartorelli G, Okamoto OK, Jandrey EHF. Emergent and underexplored oncolytic viruses for treating pediatric central nervous system tumors. EJC Paediatr Oncol. 2024, 3:100151. 10.1016\/j.ejcped.2024.100151","journal-title":"EJC Paediatr Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial","volume":"25","author":"Geletneky K","year":"2017","unstructured":"Geletneky K, Hajda J, Angelova AL, et al.. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial. Mol Ther. 2017, 25:2620-34. 10.1016\/j.ymthe.2017.08.016","journal-title":"Mol Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara H","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016, 107:1373-9. 10.1111\/cas.13027","journal-title":"Cancer Sci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Bourgeois-Daigneault MC","year":"2018","unstructured":"Bourgeois-Daigneault MC, Roy DG, Aitken AS, et al.. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018, 10:1641. 10.1126\/scitranslmed.aao1641","journal-title":"Sci Transl Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin D","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023, 8:156. 10.1038\/s41392-023-01407-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092183","article-title":"Targeting sphingolipid metabolism as a therapeutic strategy in cancer treatment","volume":"14","author":"Janneh AH","year":"2022","unstructured":"Janneh AH, Ogretmen B. Targeting sphingolipid metabolism as a therapeutic strategy in cancer treatment. Cancers (Basel). 2022, 14:2183. 10.3390\/cancers14092183","journal-title":"Cancers (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01469","article-title":"Clinical characteristics and prognostic factors of early and late recurrence after definitive radiotherapy for nasopharyngeal carcinoma","volume":"10","author":"Li F","year":"2020","unstructured":"Li F, Chen FP, Chen YP, et al.. Clinical characteristics and prognostic factors of early and late recurrence after definitive radiotherapy for nasopharyngeal carcinoma. Front Oncol. 2020, 10:1469. 10.3389\/fonc.2020.01469","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447380-a-decade-of-oncolytic-virotherapy-in-pediatric-cancers-a-systematic-review-of-safety-immune-awakening-and-emerging-efficacy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:35:32Z","timestamp":1768667732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447380-a-decade-of-oncolytic-virotherapy-in-pediatric-cancers-a-systematic-review-of-safety-immune-awakening-and-emerging-efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.101744","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,17]]}}}